Evoke Pharma (NASDAQ:EVOK) Receiving Somewhat Positive News Coverage, Study Shows

Media coverage about Evoke Pharma (NASDAQ:EVOK) has been trending somewhat positive this week, Accern Sentiment reports. The research group ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Evoke Pharma earned a coverage optimism score of 0.02 on Accern’s scale. Accern also assigned news stories about the specialty pharmaceutical company an impact score of 45.8263435531057 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Evoke Pharma (NASDAQ EVOK) opened at $2.62 on Friday. Evoke Pharma has a fifty-two week low of $2.16 and a fifty-two week high of $4.55. The stock has a market cap of $40.38, a PE ratio of -2.79 and a beta of 1.09.

Evoke Pharma (NASDAQ:EVOK) last issued its earnings results on Tuesday, November 14th. The specialty pharmaceutical company reported ($0.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.13). During the same quarter in the previous year, the firm posted ($0.29) earnings per share. research analysts forecast that Evoke Pharma will post -1 earnings per share for the current fiscal year.

EVOK has been the subject of a number of recent research reports. HC Wainwright reiterated a “buy” rating and issued a $9.00 target price on shares of Evoke Pharma in a report on Monday, September 18th. Zacks Investment Research downgraded shares of Evoke Pharma from a “hold” rating to a “sell” rating in a report on Friday, December 1st. ValuEngine downgraded shares of Evoke Pharma from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. FBR & Co reiterated a “buy” rating and issued a $10.00 target price on shares of Evoke Pharma in a report on Monday, October 30th. Finally, B. Riley restated a “buy” rating and set a $10.00 price objective on shares of Evoke Pharma in a report on Wednesday, November 15th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $9.00.

COPYRIGHT VIOLATION WARNING: This piece of content was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at https://stocknewstimes.com/2018/01/12/evoke-pharma-evok-given-daily-media-impact-score-of-0-02.html.

About Evoke Pharma

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Insider Buying and Selling by Quarter for Evoke Pharma (NASDAQ:EVOK)

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply